INVESTORS & MEDIA

Press Releases

Press Releases

Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate
December 9, 2019
- PBCAR0191 continues to be associated with no serious adverse events or dose limiting toxicities observed to date, and no cases of graft-versus-host disease- -Seven of nine treated patients (78%) had objective evidence of tumor shrinkage at any timepoint- -R/R non-Hodgkin lymphoma (NHL) cohort...
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
November 6, 2019
-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia- -Abstract summarizes early results from first three patients with advanced NHL treated with PBCAR0191 at...
Precision BioSciences to Present at Upcoming Industry and Investor Conferences
September 26, 2019
Company to Participate in the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, Chardan Genetic Medicines Conference and Jefferies Gene Therapy Summit DURHAM, N.C., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to...
Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer
September 23, 2019
DURHAM, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® platform, announced today that David Thomson, PhD, has been appointed to the position of...
Precision BioSciences to Present at Upcoming Scientific Conferences
September 4, 2019
DURHAM, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, is participating in several upcoming presentations on chimeric...
Displaying 1 - 10 of 27

INVESTORS & MEDIA

Investor Tools